Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (122)	11/8/1998 9:07:00 PM
From: arnie h	Read Replies (1) \| Respond to of 1386

David: While you make a good point about PARS needing money for phase 3 trials of HU 211, I would be most disappointed if Agis turned out to be our partner. The reason is that a more respected, large outfit adds not only money to the mix but, more importantly, credibility to the program. With appropriate partnership and credibilty, you'll see a significant up move in stock price along with a much better chance of a successful study. I doubt the street would be impressed with an arrangement with Agis and possibly look on that as a negative since it could be interpreted that we were not able to interest a select company. Regards, Arnie